A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1440

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Prostatic Neoplasms

Interventions

DRUG: Ifinatamab deruxtecan
DRUG: Docetaxel
DRUG: Prednisone
DRUG: Rescue Medication

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]